Glomerular disorder

This study tests whether the Butantan-Dengue vaccine is safe and works well in people aged 12–59 with autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are stable on low or no immune-suppressing drugs. Participants receive one vaccine dose and are monitored f…

This study tests whether combining two immune-suppressing drugs, rituximab and cyclosporine, can safely reduce protein leakage in the urine of people with membranous nephropathy, a kidney disease where the immune system attacks the kidneys. About 30 adults with persistent high pr…

This phase 2 trial tests an oral drug called ManNAc in 30 adults with primary focal segmental glomerulosclerosis (FSGS), a kidney disease that causes scarring and protein loss. Participants take ManNAc powder dissolved in water twice daily for 14 weeks. The study aims to see if t…

This study tests if obinutuzumab can help teens and children with lupus nephritis, a serious kidney complication of lupus. About 40 participants aged 5 to 17 will receive either the drug or a placebo. The goal is to see if the drug improves kidney function and reduces protein in …

This trial investigates whether pioglitazone, a drug used for diabetes, can help protect the kidneys in people with ANCA-associated vasculitis—a rare autoimmune disease that causes inflammation of blood vessels, often damaging the kidneys. Participants receive either pioglitazone…

This study tests a drug called surovatamig in 43 adults with primary membranous nephropathy, a kidney disease caused by antibodies attacking the kidneys. The drug is given as a shot under the skin. Researchers want to see if it is safe and can reduce protein in the urine, which i…

This study tests a drug called felzartamab in people with IgA nephropathy, a kidney disease where abnormal antibodies build up and damage the kidneys. The goal is to see if felzartamab can reduce protein in the urine, a sign of kidney damage. About 454 adults will receive either …

This early-phase trial is testing a new drug called MTS109, made with mRNA technology, for people with moderate to severe autoimmune diseases like lupus and scleroderma. Fifteen participants will receive several injections over a month to see if it is safe and tolerable. The goal…

This Phase 3 trial tests the drug benralizumab (Fasenra) in children aged 6 to 17 with two rare eosinophilic diseases: EGPA and HES. The study aims to see if the drug is safe, how it works in the body, and whether it can help control the disease. Fourteen children will receive in…

This study tests a drug called mosunetuzumab in 30 people with lupus, a disease where the immune system attacks the body. The goal is to see if the drug can put lupus into remission so that participants can stop most lupus medications for at least 6 months. However, some people m…

This study tests a new gene therapy, PS-002, for adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The therapy aims to control the disease in people who are at high risk of getting worse despite current treatments. Participants receive a single dose a…

This study tests a new drug, povetacicept, against a standard treatment (calcineurin inhibitor) in 176 adults with primary membranous nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the new drug can put the disease into remission more safely a…

This Phase 2 study tests atacicept, a drug that may reduce immune system attacks on the kidneys. About 250 adults with various autoimmune kidney diseases (like IgA nephropathy or membranous nephropathy) will receive weekly injections. Researchers will check safety and measure cha…

This early-phase trial tests a new treatment called KN5501, which uses specially engineered immune cells (CAR NK cells) to target and destroy harmful B cells in people with relapsed or refractory immune nephropathy, a kidney disease caused by the immune system attacking the kidne…

This study is monitoring the safety and effectiveness of the drug iptacopan (Fabhalta) in 21 Korean adults with paroxysmal nocturnal hemoglobinuria (PNH) or C3 glomerulopathy (C3G). Researchers will track side effects and lab results from routine medical records. The goal is to s…

This Phase 3 trial tests whether mezagitamab, an injectable drug, can reduce protein in the urine and preserve kidney function in adults with IgA nephropathy, a condition where immune complexes damage the kidneys. About 347 participants will receive either mezagitamab or a placeb…

This Phase 3 trial is testing a new gel called SNP-ACTH (1-39) against the standard drug rituximab in 148 adults with primary membranous nephropathy, a rare kidney condition. The goal is to see if the gel can better reduce protein in the urine and protect kidney function over 24 …

This phase 2 trial tests a one-time treatment called CC-97540, made from a patient's own immune cells engineered to target and calm the overactive immune system in lupus. The study enrolls 89 adults with active lupus (including kidney inflammation) who have not responded well to …

This Phase 2 study tests a new drug called ADX-038, alone or with another drug (telitacicept), in 30 Chinese adults with kidney diseases caused by an overactive complement system (IgA nephropathy, C3G, or IC-MPGN). The goal is to see if the treatment is safe and can help control …

This study tests an experimental tablet, BI 764198, in adults and some teens with four types of kidney disease that cause protein in the urine. Participants take the drug or a placebo daily for 20 weeks while continuing their usual care. The main goal is to see if the drug lowers…

This study tests a drug called zigakibart in 32 adults with IgA nephropathy, a kidney disease. The goal is to see if it can reduce signs of kidney damage and slow disease progression. Participants must have a recent kidney biopsy and persistent protein in their urine despite stan…

This study tests a one-time treatment called Obe-cel, made from a patient's own immune cells, for severe lupus nephritis that hasn't improved with standard care. About 35 people aged 12 to 65 will receive the infusion and be monitored for up to 24 months. The main goal is to see …

This early-stage trial tests whether BHV-1400 is safe and tolerable for people with IgA nephropathy, a kidney disease. About 20 participants with confirmed IgA nephropathy will receive the drug subcutaneously. The main goal is to check for side effects and lab abnormalities.

This study tests an oral medication called BI 764198 for people with a kidney condition called focal segmental glomerulosclerosis (FSGS). About 286 adults and teens will take either the study drug or a placebo daily for up to 2 years, while continuing their usual FSGS treatments.…

This Phase 2 trial tests whether adding belimumab to standard rituximab treatment helps more people with primary membranous nephropathy achieve remission. The study enrolls 58 adults with confirmed disease. Belimumab targets new immune cells, while rituximab depletes existing one…

This study tests whether artificial intelligence can help doctors personalize rituximab doses for people with membranous nephropathy, an autoimmune kidney disease. About 120 adults with active disease will receive either standard rituximab or AI-guided dosing to keep drug levels …

This study tests if a new drug called cenerimod can help people with lupus who have active kidney disease (lupus nephritis). About 300 adults will take either cenerimod or a placebo daily for 76 weeks, on top of their usual treatments. The main goal is to see if cenerimod improve…

This study tests whether the drug avacopan can help children aged 6 to 18 with a rare autoimmune disease called ANCA-associated vasculitis, which causes inflammation of blood vessels. About 20 participants will receive avacopan alongside standard treatments like rituximab or cycl…

This study is checking the long-term safety of a drug called avacopan for people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. About 300 adults who need treatment for a new diagnosis or flare-up will take avacopan or a placebo. The…

This study tests an experimental drug called ALXN1920 in 30 adults with primary membranous nephropathy, a rare kidney disease that can lead to kidney failure. Participants are at high risk for their disease getting worse. The study compares the drug to a placebo to see if it redu…

This early-stage study tests a new treatment called ALLO-329 for people with lupus, myositis, or scleroderma. The therapy uses specially engineered immune cells from a donor to target and calm the overactive immune system. The main goals are to check safety and see if it can impr…

This early-stage trial is testing two experimental drugs, vonsetamig and odronextamab, in people with lupus nephritis that has not responded to standard treatments. The main goal is to check safety and side effects over the long term. Researchers will also see if the drugs can he…

This Phase 3 study tests a new drug called felzartamab in 180 people with primary membranous nephropathy (PMN), a kidney disease where the body's immune system attacks the kidneys. Felzartamab is a lab-made antibody designed to stop that attack. The study compares felzartamab to …

This study tests a new treatment called CART19 for teens and young adults (ages 12-29) with severe lupus that hasn't improved with standard treatments. CART19 uses a patient's own immune cells, modified in a lab to target and calm the overactive immune system causing lupus. The g…

This Phase 2 study is testing a new drug called ADX-038 in 45 adults with complement-mediated kidney diseases, such as IgA nephropathy and C3G. The drug is an siRNA that targets the complement system, which is overactive in these conditions. Researchers are checking if it is safe…

This study tests a new drug called tarperprumig in 75 adults with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. The goal is to see if the drug is safe and can help control the disease by reducing inflammation. Participants will receive …

This early-stage trial tests a single infusion of CRISPR-edited immune cells (CTX112) from a healthy donor in 80 adults with severe lupus, scleroderma, or myositis that hasn't responded to standard treatments. The goal is to see if the cells are safe and can reduce disease activi…

This phase 3 trial tests sefaxersen, a drug that targets a part of the immune system, in 428 people with IgA nephropathy at high risk of kidney decline. Participants receive either sefaxersen or a placebo as a shot under the skin. The main goal is to see if the drug reduces prote…

This study tests whether adding LUPKYNIS to standard biologic therapies (belimumab, obinutuzumab, or anifrolumab) can quickly improve kidney function in people with lupus nephritis. About 150 adults with biopsy-confirmed lupus kidney disease will receive the combination treatment…

This early-phase trial tests whether adding NK cells (a type of immune cell) to the standard drug rituximab can safely help people with severe lupus or lupus-related kidney disease. The study will enroll 18 adults in China and focus on safety and signs of disease improvement. It …

This early-phase trial is testing a new treatment called zamto-cel, a CAR-T cell therapy, for people with severe lupus or scleroderma that hasn't improved with standard treatments. The study will enroll 48 participants and primarily look at safety and side effects. Participants f…

This study tests a new treatment called AZD0120 for people with severe lupus that hasn't improved with standard therapies. AZD0120 is a type of CAR T cell therapy that targets two proteins (CD19 and BCMA) on immune cells to calm the overactive immune system. The trial will enroll…

This study tests three experimental drugs—frexalimab, brivekimig, and rilzabrutinib—in people aged 16 to 75 with two rare kidney diseases: FSGS and MCD. The goal is to see if these drugs can reduce protein in the urine, a key sign of kidney damage, and help patients achieve remis…

This study tests an experimental drug called praliciguat in 60 adults with a rare kidney disease called FSGS. The goal is to see if it can reduce protein in the urine, a sign of kidney damage. Participants will first receive either the drug or a placebo for 24 weeks, then everyon…

This study looks at the long-term safety and effectiveness of the drug iptacopan in people with a rare blood disorder called atypical hemolytic uremic syndrome (aHUS). Participants must have completed a previous iptacopan study and still benefit from the drug. The goal is to moni…

This study tests an experimental therapy called NKX019, which uses specially engineered immune cells from donors to target and calm overactive immune cells in people with lupus nephritis or primary membranous nephropathy. The trial involves 120 adults who have not responded to st…

This study tests whether adding the drug iptacopan to standard treatment helps people with active lupus nephritis (kidney inflammation caused by lupus) achieve better kidney function and fewer flares. About 240 adults with confirmed lupus nephritis will receive either iptacopan o…

This study tests an experimental drug called iptacopan in 31 children aged 2 to under 18 with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the drug reduces protein in the urine, a sign of kidney damage, and to check its safety and how t…

This study looks at the long-term safety of a drug called zigakibart for adults with IgA nephropathy, a kidney disease. It is for people who have already finished a previous zigakibart study. Researchers will monitor side effects and check kidney function over 96 weeks.

This study tests whether hydroxychloroquine, a drug already used for lupus, can slow kidney function decline in people with IgA nephropathy (Berger's disease). About 334 adults with biopsy-confirmed IgA nephropathy and high protein in their urine will receive either hydroxychloro…

This study tests a one-time treatment called rapcabtagene autoleucel, made from a patient's own immune cells, for people with active lupus or lupus kidney disease that hasn't improved with standard therapies. About 179 adults will receive the treatment after a short chemotherapy …

This Phase 3 trial tests whether iptacopan can reduce protein in the urine and preserve kidney function in people with complement 3 glomerulopathy (C3G), a rare kidney disease. About 98 adults and adolescents will receive either iptacopan or a placebo for 6 to 12 months. The stud…

This early-stage study tests a new drug, GT801, in 22 adults with moderate to severe autoimmune diseases that haven't responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will also look for signs that the drug helps control the…

This study tests a drug called sparsentan in 24 adults with IgA nephropathy, a kidney disease. Some participants are newly diagnosed, others have the disease return after a kidney transplant. The goal is to see if sparsentan can reduce protein in the urine, a sign of kidney damag…

This study tests a drug called iptacopan in people with a rare kidney disease (IC-MPGN). About 106 adults and teens will receive either iptacopan or a placebo. The main goal is to see if iptacopan reduces protein in the urine and helps preserve kidney function over 18 months.

This study tests a new tablet called HSK39297 for people with IgA nephropathy, a kidney disease that can lead to kidney failure. The trial includes 73 adults who have already taken the drug in a previous study. They will take the tablet once daily for an extended period, with a p…

This study tests an experimental drug called EVER001 in 45 adults with three types of kidney disease (FSGS, MCD, or IgA nephropathy) that cause protein to leak into urine. Participants take the drug twice daily for a year. The main goal is to see if it safely reduces protein leve…

This study tests a new drug, JADE101, in 30 adults with IgA nephropathy, a kidney disease. The goal is to see if the drug is safe and can reduce protein in the urine, a sign of kidney damage. Participants must be on stable standard care and have a kidney biopsy confirming the dis…

This study tests an experimental tablet called HSK39297 in 370 adults with IgA nephropathy, a kidney disease. The goal is to see if the drug can reduce protein in the urine and slow down kidney function decline over 36 to 48 weeks. Participants will be randomly assigned to receiv…

This early-stage study tests a new treatment made from healthy donor immune cells (CAR T cells) for people with severe autoimmune diseases like lupus that haven't responded to standard therapies. The goal is to see if these cells can safely target and calm the overactive immune s…

This study tests whether dapagliflozin, a drug already used for diabetes and other kidney diseases, can help people with lupus nephritis. About 33 adults with active lupus kidney inflammation will receive either dapagliflozin or a placebo alongside their usual treatment. The main…

This early-stage study is testing a new cell therapy called FT819 for people with severe autoimmune diseases like lupus, vasculitis, and scleroderma. The treatment involves giving specially engineered immune cells along with chemotherapy drugs. The main goal is to see if it's saf…

This Phase 2 trial tests a one-time infusion of rapcabtagene autoleucel, a CAR-T cell therapy made from a patient's own immune cells, against standard treatments for severe active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). About 126 adults aged 18-7…

This study tests whether adding budesonide capsules early to standard blood-pressure and sugar-lowering drugs can reduce protein in the urine of people with IgA nephropathy, a kidney disease. Thirty adults with newly diagnosed disease will take the combination for 9 months, then …

This study tests a new treatment called QT-219CX, which uses specially engineered immune cells (CAR-T cells) to target and calm the overactive immune system in people with autoimmune diseases like lupus, kidney disease, and scleroderma. The treatment is given as a one-time infusi…

This Phase 2 trial tests an investigational drug called SHR-2173 in 84 adults with primary IgA nephropathy, a kidney disease. Participants receive either a high, medium, or low dose of SHR-2173 or a placebo for 48 weeks. The main goal is to see if the drug reduces protein in the …

This study tests an oral drug called sparsentan in 67 children with certain kidney diseases that cause protein to leak into urine. The goal is to see if the drug safely reduces protein levels over 108 weeks. Participants must have a certain level of kidney function to join.

This early-stage study tests a new drug called YKST02 in 12 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The main goal is to see if the drug is safe and tolerable, and to check if it reduces protein in the urine, a sign of kidney damage. Particip…

This study tests a new drug, B007, against the standard treatment cyclosporine for people with primary membranous nephropathy, a kidney disease that causes protein leakage. About 216 adults with confirmed disease and adequate kidney function will be randomly assigned to receive e…

This phase 2 trial is testing a new drug, budoprutug (also known as TNT119), in 45 people with primary membranous nephropathy, a kidney disease that can lead to kidney failure. The study aims to see if the drug is safe and can help patients achieve remission. Participants receive…

This early-stage trial is testing a new drug called B007, given as a shot under the skin, for people with primary membranous nephropathy — a kidney disease where the immune system attacks the kidneys. The study will include 52 adults and will focus on safety, how the drug moves t…

This study tests iptacopan, an oral drug, in 20 adults with IgA nephropathy, a kidney disease. Researchers will use kidney biopsies and lab tests to see if the drug reduces signs of inflammation and damage over 9 months. The goal is to understand if iptacopan can slow disease pro…

This early study tests whether a liquid form of the drug avacopan can be safely given through a feeding tube to critically ill patients with ANCA vasculitis who have severe lung bleeding and need a ventilator. The main goal is to measure how the drug levels change in the blood ov…

This study tests CPV-104, a new medicine designed to calm an overactive immune system part that attacks the kidneys in C3 glomerulopathy (C3G), a rare kidney disorder. It is the first time CPV-104 is given to people. The trial includes 39 participants: healthy volunteers receivin…

This Phase 3 trial is testing whether adding BDB-001 to standard treatments (cyclophosphamide, azathioprine, rituximab, or prednisone) helps more people with ANCA-associated vasculitis achieve remission. The study plans to enroll 300 adults with active GPA or MPA. Participants wi…

This study tests a noninvasive device that gently stimulates a nerve in the ear to help children with steroid-resistant nephrotic syndrome, a kidney condition that doesn't respond to standard steroids. The goal is to see if this approach is feasible and tolerable, and if it can r…

This study looks at the long-term safety and effectiveness of a drug called iptacopan for people with two rare kidney diseases: C3 glomerulopathy and IC-MPGN. About 225 adults who have already completed a previous iptacopan study will take the drug for an extended period. The goa…

This study tests a non-invasive device that gently stimulates a nerve in the ear to see if it can help control nephrotic syndrome in children aged 3-17. The goal is to reduce relapses and the need for steroids or other immune-suppressing drugs. Thirty children will be randomly as…

This early-phase trial is testing a new treatment for autoimmune disorders like lupus and scleroderma. It combines specially engineered natural killer cells (AD-PluReceptor) with a drug called tafasitamab and chemotherapy to try to control the disease. The study will enroll 47 pe…

This study tests a new treatment for adults with severe lupus that hasn't improved with standard therapies. Doctors will use a person's own immune cells, modified to target specific lupus-driving cells (CD19 or BCMA), and give them back as a one-time infusion. The goal is to cont…

This study tests whether obinutuzumab, a drug used for certain blood cancers, can help people with fibrillary glomerulonephritis (FGN), a rare kidney condition that causes protein leakage and can lead to kidney failure. Twenty adults with confirmed FGN will receive the drug intra…

This study tests a new drug called MIL116 in healthy volunteers and people with IgA nephropathy, a kidney disease. The drug is given as a shot under the skin and aims to reduce harmful antibodies that damage the kidneys. The study checks for safety, side effects, and how well the…

This study tests whether adding finerenone to standard blood pressure medications can lower protein in the urine of people with primary membranous nephropathy, a kidney condition that can lead to kidney failure. About 116 adults will be randomly assigned to receive either fineren…

This early-stage trial is testing a treatment called CABA-201 for people with active systemic lupus erythematosus (SLE), including those with lupus nephritis. CABA-201 is made from a patient's own immune cells, which are modified to target and temporarily remove B cells—a key dri…

This early-stage trial is testing Descartes-08, a cell therapy made from modified immune cells, in 50 young people aged 12 and older with four autoimmune diseases: childhood-onset lupus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis. The stu…

This phase 3 trial is for people with granulomatosis with polyangiitis (GPA), a rare autoimmune disease causing blood vessel inflammation, who did not get better with standard treatments. It compares three salvage therapies: rituximab plus another drug, tocilizumab, or tofacitini…

This study tests a drug called BAT4406F in people with two rare kidney conditions: Minimal Change Disease and Focal Segmental Glomerulosclerosis. The goal is to see if it can reduce protein in the urine and prevent the disease from coming back. About 192 participants will receive…

This early-phase trial is testing a new type of cell therapy called QT-219C, which uses donor-derived CAR-T cells to target and destroy faulty immune cells in people with severe autoimmune diseases like lupus, nephrotic syndrome, and vasculitis. The study will enroll 15 participa…

This study tests an experimental drug called WAL0921 in 96 adults with kidney diseases that cause protein in the urine, including diabetic nephropathy and several rare conditions. Participants receive either the drug or a placebo as an IV infusion every two weeks for 14 weeks, th…

This early-stage study tests a new drug called HB2198 in 30 adults with moderate to severe lupus, including kidney inflammation. The drug is designed to temporarily remove certain immune cells (B cells) that drive the disease. Participants receive two doses and are monitored for …

This study compares two ways of dosing the drug mycophenolate mofetil (MMF) for children with lupus nephritis, a kidney disease caused by lupus. One method uses a standard dose based on body size, while the other adjusts the dose based on drug levels in the blood. The goal is to …

This study tests a drug called ravulizumab in children aged 2 to 18 with a kidney disease called IgA nephropathy. The goal is to see if the drug can reduce protein in the urine, a sign of kidney damage. Participants will receive the drug through an IV and be monitored for safety …

This phase 2 trial is testing whether biologic drugs (belimumab or telitacicept) can improve kidney outcomes in people with active lupus nephritis better than standard therapy. About 50 participants will be randomly assigned to one of three treatment groups for six months. The go…

This 2-year extension study looks at lupus nephritis patients who finished a previous trial of ianalumab. Some patients who responded well will stop treatment to see if their kidney disease stays under control. Others who did not respond or were already on open-label ianalumab wi…

This study tests a new treatment called CD19 CAR T cells for people with severe lupus that hasn't improved with standard therapies. The treatment uses a patient's own immune cells, modified in a lab to target and attack faulty immune cells driving the disease. The trial aims to s…

This study tests a new treatment using a patient's own immune cells, modified to target and attack faulty immune cells that cause autoimmune diseases. It is for people with severe, hard-to-treat conditions like lupus. The goal is to see if this therapy is safe and can control the…

This study tests an experimental drug called AP1189 in people with a rare kidney condition called idiopathic membranous nephropathy, which causes severe protein leakage in urine. The trial includes 23 adults who are already on standard blood pressure medications. Participants wil…

This early-phase trial is testing a personalized cell therapy called CAR-T, designed to target and destroy faulty immune cells in people with active autoimmune diseases like lupus, scleroderma, and Sjogren's syndrome. Up to 20 participants will receive the treatment after a short…

This study tests a drug called obinutuzumab in 33 adults with a relapsing form of granulomatosis with polyangiitis (GPA, formerly Wegener's). The goal is to see if the drug can stop disease activity and turn off the related antibody. Participants will be followed for 6 months to …

This early-stage study tests a new cell therapy called YTS109 in 18 adults aged 18-65 with autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of the cells, and researchers monitor safety and…

This study tests a new treatment using a patient's own immune cells, modified to target and attack harmful cells in three severe autoimmune diseases: lupus nephritis, systemic sclerosis, and Sjogren's syndrome with pulmonary hypertension. About 45 adults will receive a single inf…

This early-stage trial is testing a new treatment called YTS109 for people with severe autoimmune diseases like lupus and Sjogren's syndrome that have come back or not responded to standard care. About 18 adults will receive a single infusion of these specially engineered immune …

This early-stage trial is testing a new treatment made from umbilical cord blood cells, called CD19-BCMA CAR-T cells, in 45 people with severe lupus, scleroderma, or Sjogren's syndrome with lung complications. The main goal is to check safety, especially serious side effects with…

This early-stage study tests a new cell therapy called YTS109 in 18 adults with severe autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of the cells, and researchers monitor safety and how…

This early-stage study tests a new cell treatment called YTS109 in 18 adults with hard-to-treat autoimmune diseases like lupus and scleroderma. Participants receive a single infusion of these specially designed cells. The main goal is to check if the treatment is safe, and also t…

This study tests whether the blood thinner rivaroxaban can prevent dangerous blood clots in people with idiopathic membranous nephropathy, a kidney disease that raises clot risk. About 134 participants at high risk for clots but low risk for bleeding will receive either rivaroxab…

This study looks at whether taking TARPEYO (budesonide) for a longer period helps adults with IgA nephropathy, a kidney disease. Participants have already taken the drug for 9 months and will now take it for another 15 months. The main goal is to see if protein levels in urine st…

This early-phase study tests a new treatment called anti-CD19/BCMA universal CAR T cells (KN3601) for people with relapsed or refractory immune-mediated kidney disease. The therapy involves collecting a patient's immune cells, engineering them to target and destroy harmful B cell…

This early-stage study is testing a universal donor CAR T-cell therapy that targets two proteins (CD19 and BCMA) on immune cells that drive autoimmune diseases. The goal is to see if it is safe and can help control conditions like lupus, kidney disease, and vasculitis. About 15 p…

This early-phase trial is testing a new treatment for children with B cell-related autoimmune diseases like lupus and kidney disease. The therapy uses specially engineered natural killer (NK) cells that target and destroy faulty immune cells. Only 12 children will take part, and …

This early-phase study tests a new treatment called RD06-05, which uses a patient's own immune cells modified to target and reset the immune system in autoimmune diseases like lupus, multiple sclerosis, and vasculitis. The goal is to check safety and how well the body tolerates i…

This study tests an experimental drug, DMX-200, in people with a rare kidney condition called FSGS. The drug aims to reduce protein leakage in urine and slow down kidney damage. About 286 adults and teens (ages 12-80) who are already on standard blood pressure medication will rec…

This study tests whether the diabetes drug metformin can protect kidney cells in people with a rare kidney disease called FSGS. About 30 adults will receive either metformin or a placebo for 6 months, alongside their usual treatments. The goal is to see if metformin reduces kidne…

This phase 3 trial is testing whether a 4-week low-dose steroid regimen, given alongside standard drugs like rituximab or cyclophosphamide, is safer and as effective as the usual longer steroid treatment for ANCA vasculitis with severe kidney problems. The study will enroll 36 pe…

This Phase 2 trial tests an experimental drug called SHR-2173 in 75 adults with primary membranous nephropathy, a kidney condition that can lead to kidney failure. The drug is given as an injection over several doses. Researchers are checking if it is safe and can help control th…

This early-stage study tests an experimental drug called UB-VV410 in 21 adults with active lupus (including lupus nephritis) that hasn't improved with standard treatments. The main goals are to check safety, find the best dose, and see early signs of effectiveness. Participants w…

This study tests an experimental pill called HSK39297 for people with lupus nephritis, a kidney complication of lupus. About 105 adults will receive either 200 mg, 300 mg, or a placebo daily for several weeks. The main goal is to see if the drug reduces protein in the urine, a si…

This early-stage study tests a new treatment called RXIM002 for people with severe autoimmune diseases that haven't responded to standard therapies. The treatment uses a special RNA molecule to create immune cells that target and destroy faulty B cells, which are causing the dise…

This study compares a newer targeted drug, obinutuzumab, against a standard treatment (cyclophosphamide plus steroids) for primary membranous nephropathy, a kidney disease that can lead to kidney failure. About 144 adults with moderate to severe protein in their urine will receiv…

This early-stage study is testing a new type of cell therapy (called QT-019C) in 12 adults with severe autoimmune diseases like lupus and scleroderma that have not responded to standard treatments. The therapy uses specially engineered immune cells from a healthy donor to target …

This program provides access to EXV811, atrasentan for people with IgA nephropathy, a serious kidney disease. It is for patients who have no other treatment options and cannot join a clinical trial. The goal is to offer potential benefit when standard therapies are not available.

This early-phase study tests a single injection of a gene therapy called V001-BCMA for people with autoimmune diseases like lupus that have not responded to standard treatments. The therapy targets and modifies specific immune cells to reduce disease activity. The main goal is to…

This study tests whether starting budesonide capsules early can help people with IgA nephropathy, a kidney disease. About 200 adults with recent diagnosis and high protein in urine will take the drug for 12 months. Researchers will measure changes in protein levels and kidney fun…

This early-stage trial tests a new daily pill, IPG11406, in 36 adults with lupus nephritis—a kidney complication of lupus. The study checks if the drug is safe and whether it can reduce protein in the urine and improve kidney function. It is too soon to know if it works, but the …

This study tests a drug called obinutuzumab in 20 adults with a high-risk form of membranous nephropathy, a kidney disease caused by antibodies attacking the kidneys. The goal is to see how quickly the drug lowers those harmful antibodies and whether it leads to remission. Partic…

This study tests a new treatment using specially engineered immune cells (CAR-NK) from cord blood for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis that haven't responded to standard therapies. The goal is to see if it's safe and can control the d…

This early-phase trial tests whether a personalized immune cell therapy called CAR-T can safely treat a severe, hard-to-control kidney condition called refractory membranous nephropathy. Five adults with confirmed disease will receive a single infusion of engineered cells after m…

This study tests an experimental drug called RG002C0106 in 30 adults with IgA nephropathy, a kidney disease. The goal is to see if the drug safely reduces protein in urine, a sign of kidney damage. Participants receive either the drug or a placebo, and neither they nor their doct…

This study tests an experimental drug called VIB4920 in people with active lupus nephritis, a serious kidney complication of lupus. About 74 adults will receive either VIB4920 or a placebo, along with standard medications, to see if the drug helps improve kidney function. The goa…

This early-phase study is testing a new cell therapy called LUCAR-DKS1 in 36 adults with relapsed or refractory autoimmune diseases like lupus. Participants receive their own modified NK cells after a short chemotherapy prep. The main goals are to check safety, find the right dos…

This study compares different immune-suppressing drugs to treat a kidney disease called idiopathic membranous nephropathy. About 200 adults with high protein in their urine will receive one of several treatments. The goal is to see which drug works best to reduce protein leakage …

This program provides early access to the drug iptacopan for people with serious or life-threatening C3 glomerulopathy (C3G) or paroxysmal nocturnal hemoglobinuria (PNH) who have no other treatment options. It is designed for patients who cannot join a clinical trial or have exha…

This study tests a new drug, SHR-1703, for people with eosinophilic granulomatosis with polyangiitis (EGPA), a rare disease that causes inflammation in blood vessels. The trial will include 166 adults who have not responded well to standard treatments. The goal is to see if SHR-1…

This study tests an experimental drug called SHR-2173 for people with active lupus nephritis, a kidney complication of lupus. About 51 adults will receive either the drug or a placebo to see if it improves kidney function and reduces protein in urine. The goal is to control the d…

This early-phase trial is testing a new type of cell therapy (CAR-NK cells) in 36 children with B-cell-related autoimmune diseases like lupus and certain kidney diseases. The therapy uses specially designed immune cells to target and potentially control the overactive immune syst…

This Phase 3 trial tests whether a drug called obinutuzumab, combined with mycophenolate mofetil (MMF), can control lupus nephritis without the need for oral steroids. About 196 people with active lupus kidney disease will be randomly assigned to either the obinutuzumab/MMF regim…

This early-phase study tests whether a new drug called ONT01 is safe for people with lupus nephritis or systemic lupus erythematosus (SLE). About 61 participants will receive ONT01 alongside their usual lupus medications. The goal is to find the highest safe dose and see if it im…

This Phase 2 trial tests whether adding ALE.F02 to standard therapy can protect kidney function in people with ANCA-associated vasculitis, an autoimmune disease that attacks small blood vessels, often damaging the kidneys. About 80 participants will receive either a low, high, or…

This early-stage study tests a new drug, YK012, in 72 adults with primary membranous nephropathy, a kidney disease that causes protein leakage. The main goals are to check safety and how the body processes the drug, with a first look at whether it helps reduce protein in urine. P…

This study tests a new drug (HLX79) combined with an existing antibody treatment (rituximab) for people with active kidney inflammation called glomerulonephritis. About 24 adults with membranous nephropathy or lupus-related kidney disease will receive either the new drug or a pla…

This study tests whether combining two medications, belimumab and voclosporin, along with standard therapy, can help more people with lupus-related kidney disease achieve complete remission. About 30 adults with active lupus nephritis will take part. The goal is to see if this co…

This phase 2 trial tests whether adding avacopan (a pill that blocks inflammation) to low-dose steroids can help people with crescentic IgA nephropathy, a severe kidney condition. Sixteen adults with high-risk features will be randomly assigned to receive either avacopan plus low…

This early-stage study tests a new treatment called RD06-05, a universal CAR-T cell therapy, in up to 84 adults with autoimmune diseases like lupus, vasculitis, and scleroderma. The therapy targets and removes faulty immune cells to help control the disease. The main goal is to c…

This early-stage study tests a new treatment for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard therapies. The treatment uses specially engineered immune cells (CAR T-cells) from a healthy donor to target and potentially rese…

This study tests a liquid medication called ACE Reno, taken under the tongue four times daily for 12 weeks, in 300 adults with chronic kidney disease from diabetes, high blood pressure, autoimmune disorders, or other causes. The goal is to see if it safely reduces protein in the …

This study monitors the safety and effectiveness of the drug LUPKYNIS (voclosporin) in 400 adults with lupus nephritis under real-world conditions. Participants take LUPKYNIS alongside standard medications like steroids. The goal is to track side effects and see how well the drug…

This early-stage trial tests a new drug called VIS171 in 30 people with lupus, alopecia areata, or a kidney condition called FSGS. The main goal is to check safety and how the body handles the drug. Participants receive VIS171 as a shot under the skin, alongside their usual care,…

This study tests a drug called daratumumab in 40 people with a rare kidney condition called PGNMID, where abnormal proteins damage the kidneys. Participants receive weekly injections for 8 weeks, then every two weeks for another 8 weeks. The goal is to see if the drug can reduce …

This study looks at whether continuing a low dose of prednisone (5 mg/day) for an extra 12 months can help people with a type of blood vessel inflammation called ANCA-associated vasculitis stay in remission. About 146 adults who are already in remission and receiving rituximab wi…

This study tests whether combining budesonide (Nefecon) and ambrisentan can reduce protein in the urine and preserve kidney function in people with IgA nephropathy who are at risk of kidney failure. About 129 adults will take both pills daily for 36 weeks. Researchers will measur…

This study is testing an artificial intelligence model that reads kidney biopsy images to diagnose chronic kidney disease. Researchers will compare the AI's results to the standard diagnosis made by pathologists. About 2,900 patients with chronic glomerulonephritis will participa…

This study is testing a new type of PET scan tracer (68Ga-FAPI) to see if it can better detect lung and kidney problems in people with ANCA-associated vasculitis, a rare autoimmune disease. The tracer targets specific cells linked to tissue scarring. Researchers will enroll 30 ad…

This study is testing whether a urine test can detect lupus nephritis, a serious kidney complication of lupus, as accurately as a standard kidney biopsy. Researchers will collect urine and blood samples from 40 lupus patients with kidney problems and compare the results to their …

This study looks at whether measuring certain antibodies in the blood can help diagnose and monitor idiopathic nephrotic syndrome, a kidney condition that causes swelling and protein loss. Researchers will test blood samples from 100 adults with different forms of the disease and…

This study is testing a new blood-based test that aims to predict which medication will work best for each person with rheumatic diseases like rheumatoid arthritis or lupus. Researchers will take a blood sample and analyze immune cells to create a personalized treatment profile. …

This study compares two types of ultrasound-guided nerve blocks for pain control after open kidney removal surgery. Ninety adults will receive either a rhomboid intercostal sub-serratus plane block or an external oblique intercostal block. Researchers will measure how long it tak…

This study tests whether letting a bladder catheter fall out on its own (passive removal) is better than having a nurse pull it out (active removal) after urological surgery. 160 men will be randomly assigned to one method. Researchers will measure satisfaction, pain, and anxiety…

This study aims to learn more about how lupus (SLE) develops and changes over time by observing patients and their relatives. Up to 2000 people aged 3 and older with known or suspected lupus, along with their family members, will provide medical history, blood and urine samples, …

This study follows up to 2000 people with immune-related kidney diseases, such as nephrotic syndrome and lupus nephritis. Researchers will collect medical history, lab tests, and blood or urine samples to better understand these conditions. The goal is to learn more about causes …

This study follows 300 adults with lupus nephritis who are already taking belimumab as part of their routine care. Researchers will track kidney function for up to 5 years to see how well the drug preserves renal health and prevents the need for dialysis or transplant. The goal i…

This study investigates how changes in kidney cell metabolism relate to the rate of kidney function decline in people with ANCA vasculitis and other kidney diseases. Researchers will analyze kidney biopsy samples and blood/urine tests from 146 participants over one year. The goal…

This study follows 500 adults with lupus to see if blood and urine tests can reliably detect kidney inflammation (lupus nephritis). Participants give samples during routine visits, and doctors track their kidney health over time. The goal is to find simple, non-invasive markers t…

This study is collecting blood, urine, and fecal samples from 100 people with ANCA-associated vasculitis, a rare autoimmune disease. Researchers will follow participants for up to 5 years, tracking relapses and complications. The goal is to identify factors that predict disease f…

This study looks at how ANCA-associated vasculitis affects the eyes. Researchers will use a special imaging test called OCT angiography to examine blood vessels in the eyes of 70 participants. The goal is to better understand and detect eye involvement early, which could help pre…

This observational study will follow 800 adults with IgA nephropathy, a common kidney disease, to see how well current treatments control protein in the urine and preserve kidney function over 12 months. Researchers want to understand why some patients do not respond to standard …

This study is collecting blood, urine, and kidney tissue samples from 144 children and adults with a kidney condition called nephrotic syndrome. The goal is to build a large database and sample collection to study how the immune system and kidney cells interact. Researchers hope …

This study follows up to 4,000 people with vasculitis (a group of diseases that cause blood vessel inflammation) and healthy volunteers over many years. Researchers collect blood, urine, imaging, and genetic samples to learn how the disease develops and changes. The goal is to fi…

This study is gathering information from 400 adults in France diagnosed with membranous nephropathy, a rare kidney condition. Researchers will track how the disease progresses over one year, looking at remission rates and possible environmental or genetic risk factors. The goal i…

This study is for people with rare kidney diseases like Minimal Change Disease, Focal Segmental Glomerulosclerosis, and Membranous Nephropathy. Researchers will collect health information and biological samples from 1,200 participants over many years. The goal is to better unders…

This study helps people with certain kidney diseases (like nephrotic syndrome and FSGS) find clinical trials that match their specific disease profile. Researchers analyze participants' molecular data to recommend targeted therapies in ongoing trials. The goal is to improve treat…

This study is observing 223 people with active lupus (including kidney inflammation) who haven't gotten better with steroids and at least two immunosuppressants. Researchers want to see how well today's standard treatments work for these tough cases. The goal is to measure how ma…

This early-stage study is testing a new oral drug called SK-09 in 72 healthy adults to see if it is safe and how the body processes it. The study is split into two parts: one where participants get a single dose, and another where they get multiple doses. No one knows who gets th…

This study aims to learn how well heart scans (MRI, ultrasound, PET) can detect and predict outcomes in people with suspected or known inflammatory heart diseases. Researchers will follow 5,000 adults for one year to see how often heart involvement is confirmed and how it affects…

This study is collecting medical information and biological samples (like blood, urine, and kidney tissue) from 300 people with FSGS or MCD who have had or will have a kidney transplant. The goal is to build a research biobank called RESOLVE to help scientists study why these dis…

This study is building a large registry and biorepository of 3,500 adults with systemic lupus erythematosus (SLE), including those with lupus nephritis and neuropsychiatric lupus. Participants will provide clinical data and biospecimens over time, creating a resource for future r…

This study follows 2000 Chinese patients with IgA nephropathy who still have relatively good kidney function. Researchers will test their blood and urine for biomarkers that might predict if and when their kidney disease gets worse. No new treatment is being tested; the goal is t…

This study is investigating whether certain autoantibodies, especially those targeting a protein called nephrin, play a role in nephrotic syndrome, a kidney condition that causes swelling and protein loss in urine. Researchers will analyze blood and kidney tissue from 50 children…

This early-stage study tests a new drug called CMS-D017 in 88 healthy adults to see if it is safe and how the body processes it. The drug is being developed for two rare conditions: paroxysmal nocturnal hemoglobinuria (a blood disorder) and complement-mediated kidney disease. Par…

This study is for older adults, including those in the hospital or with low priority care needs. Researchers want to see if newer methods, like body scans and blood tests, can better detect malnutrition and kidney problems than current standard tests. The goal is to make diagnosi…

This study aims to see if a special cell culture system can detect a substance in the blood that causes protein leakage in the urine of people with a kidney condition called nephrotic syndrome. Researchers will compare blood and urine samples from 150 participants, including pati…

This study aims to improve diagnosis for people with rare genetic diseases whose standard genetic tests came back negative. Researchers will take a small skin sample and analyze RNA to find hidden genetic changes. The study involves 105 participants, including healthy volunteers …

This observational study follows 500 adults with primary membranous nephropathy and nephrotic syndrome who are treated with rituximab or other monoclonal antibodies. Researchers aim to describe long-term disease outcomes and identify predictors of remission or progression. The st…

This study is investigating why some people with membranous nephropathy, a kidney disease, respond well to a treatment that depletes certain immune cells (B-cells) while others do not. Researchers will analyze blood samples from 86 patients and healthy volunteers to compare immun…

This study follows up to 1,180 children in France with a rare kidney condition called idiopathic nephrotic syndrome. Researchers will collect information on disease patterns, treatments, and side effects to build a detailed database. The goal is to better understand the disease a…

This study examines 30 adults with idiopathic nephrotic syndrome, a kidney condition that can lead to kidney failure. Researchers will analyze blood immune cells and bacteria from stool and urine samples to see if changes in gut or urinary bacteria are linked to immune system pro…

This early-stage study tests the safety of a new drug, CLYM116, in 48 healthy adults aged 18-60. Participants receive either the drug or a placebo by injection, and researchers monitor for side effects and how the drug moves through the body. The study is not designed to treat an…

This study follows about 70 people who have already received KYV-101, a CAR T-cell therapy, for autoimmune diseases like lupus and multiple sclerosis. Researchers will monitor participants for up to 15 years to track any delayed side effects, new cancers, or other health problems…

This study is testing whether a special full-body PET scan can more accurately detect active ANCA-associated vasculitis (AAV) and predict long-term heart disease risk. Researchers will scan up to 120 participants (some with active AAV, some healthy) using three different tracers …

This study tests a new method to help patients understand complex spine or prostate surgeries before they agree to them. Instead of just reading a form, patients watch multimedia content and answer questions to check their understanding. The goal is to see if this approach makes …

This study looks at how well three AI models—ChatGPT, Gemini, and Deepseek—can diagnose and suggest treatments for urology diseases. Researchers will use 800 past patient records from four hospitals to check the AI's accuracy and usefulness. The goal is to understand if AI can he…

This study is a fully online registry for adults and children with lupus. Participants fill out surveys every six months about their symptoms, treatments, and quality of life. The goal is to collect real-world data to improve care and guide future research. No travel or clinic vi…

This study tracks the pregnancy experiences of women with vasculitis, a group of rare diseases causing blood vessel inflammation. Researchers will use online surveys to understand how vasculitis affects pregnancy and what outcomes occur. The goal is to gather information to help …

This study follows 700 people with eosinophilic granulomatosis with polyangiitis (EGPA), a rare immune disorder causing asthma, high eosinophil levels, and blood vessel inflammation. Researchers aim to discover biological markers that can measure disease activity and predict trea…

This study collects tissue samples from 1,000 people with various forms of vasculitis, a group of rare inflammatory blood vessel diseases. Researchers will analyze the samples alongside clinical data to identify genes that increase risk and to spark new ideas for diagnosis and tr…

This study looks at skin samples from 50 people with different types of vasculitis, a condition where blood vessels become inflamed. Researchers want to understand how the disease affects the skin at a molecular level. Participants must have an active skin rash related to their v…

This study collects DNA samples and medical information from 1,000 people with various forms of vasculitis (blood vessel inflammation). Researchers will analyze the data to identify genes that increase the risk of developing these severe diseases. The goal is to better understand…

Researchers at the University of Michigan and Northwestern University are interviewing children, adults, and parents of young children about their experiences with swelling caused by Nephrotic Syndrome. The goal is to develop a survey that can be used in future clinical trials to…

This study looks at blood and kidney tissue from 150 adults with IgA nephropathy or related kidney diseases. Researchers want to find unique patterns in immune cells that cause kidney damage. The goal is to develop a blood test that could diagnose the disease without a painful ki…

This study collects medical data from 60 adults diagnosed with either EGPA or HES, two rare conditions that cause high levels of a type of white blood cell. Researchers will use artificial intelligence to find patterns that help doctors tell the diseases apart and predict how pat…

This study looks at why some kidney transplant patients, especially those with a kidney disease called FSGS, develop protein in their urine again after surgery. Researchers will examine blood and kidney tissue samples taken before and after the transplant to find the cause. The g…

This registry is gathering health information and biological samples from 500 people with focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD), two rare kidney conditions. Researchers will track participants over 10 years to understand how these diseases prog…

This study looks at whether doing a repeat kidney biopsy one year after starting treatment for lupus nephritis can help doctors decide if more treatment is needed. Half of the 206 participants will get the repeat biopsy, and the other half will follow standard care. The goal is t…